Prosecution Insights
Last updated: July 17, 2026
Application No. 18/277,713

ARTIFICIAL IMPLANT AND METHOD FOR MANUFACTURING SAME

Non-Final OA §102§103
Filed
Aug 17, 2023
Priority
Feb 18, 2021 — RE 10-2021-0022039 +2 more
Examiner
DUDDEN, TERESA MARIE
Art Unit
3774
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Osstemimplant Co. Ltd.
OA Round
1 (Non-Final)
42%
Grant Probability
Moderate
1-2
OA Rounds
11m
Est. Remaining
82%
With Interview

Examiner Intelligence

Grants 42% of resolved cases
42%
Career Allowance Rate
10 granted / 24 resolved
-28.3% vs TC avg
Strong +40% interview lift
Without
With
+40.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
24 currently pending
Career history
70
Total Applications
across all art units

Statute-Specific Performance

§103
92.9%
+52.9% vs TC avg
§102
4.4%
-35.6% vs TC avg
§112
1.7%
-38.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 24 resolved cases

Office Action

§102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Claims 2, 5 and 8-12 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 04/13/2026. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1, 3-4 and 7 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Schuessler (US 2019/0175332 A1). Regarding claim 1, Schuessler teaches an artificial implant (20, breast implant, fig. 1) comprising: a silicone shell (22, , fig. 1, ¶ [0023]) consisting of an upper portion (see annotated fig. 1, below), a lower portion (see annotated fig. 1, below), and a side portion (see annotated fig. 1, below); and a filler injected into the silicone shell (24, fluid, fig. 1), wherein the silicone shell includes one or more silicone layers (52, inner layer, fig. 7) and one or more reinforcing layers (54, intermediate layer, fig. 7) formed on at least a portion of a surface of the silicone layer (fig. 7), and the reinforcing layer is provided in at least a portion of the lower portion and side portion of the silicone shell (fig. 1). PNG media_image1.png 275 555 media_image1.png Greyscale Regarding claim 3, Schuessler further teaches at least a portion of the silicone shell is formed by continuously or alternately laminating the one or more silicone layers and the one or more reinforcing layers (¶ [0023] and ¶ [0040], fig. 7). Claim 3 is a product by process claim. Patentable weight has only been given to the structure of the end product, not to the method of manufacture. The end product being considered a layered silicone shell. Manufacturing steps such as continuously or alternately laminating the silicon and reinforcing layers is not given patentable weight in the claim. “[E]ven though product-by-process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process” (See MPEP 2113). Regarding claim 4, Schuessler further teaches the silicone shell has a thickness of 0.4 to 1.2 mm (¶ [0032]), and the reinforcing layer has a thickness of 0.01 to 0.3 mm (¶ [0032]). Regarding claim 7, Schuessler further teaches a cross-section of the artificial implant has one shape selected from a circular shape, an oval shape, and a teardrop shape (fig. 1, ¶ [0022]). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Schuessler (US 2019/0175332 A1). Regarding claim 6, Schuessler fails to explicitly state the silicone shell in which the reinforcing layer is provided has a rupture strength of 25 to 50 N and/or an elongation rate of 400 to 520%. The reinforced area of the implant of Schuessler increases rupture resistance in increase elongation (¶ [0060]). It would have been obvious to one having ordinary skill in the art at the time the invention was made to the silicone shell in which the reinforcing layer is provided to have a rupture strength of 25 to 50 N and/or an elongation rate of 400 to 520%, since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art (see MPEP 2144). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to TERESA M DUDDEN whose telephone number is (571)272-0435. The examiner can normally be reached Monday - Friday 7:30 am - 5:00 pm EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, THOMAS BARRETT can be reached at (571) 272-4746. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /T.M.D./Examiner, Art Unit 3774 /THOMAS C BARRETT/SPE, Art Unit 3799
Read full office action

Prosecution Timeline

Aug 17, 2023
Application Filed
May 15, 2026
Non-Final Rejection mailed — §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12653673
ANNULAR AUGMENTATION DEVICE FOR CARDIAC VALVE REPAIR
5y 3m to grant Granted Jun 16, 2026
Patent 12648854
ARTIFICIAL JOINT STEM
3y 6m to grant Granted Jun 09, 2026
Patent 12594167
HIP IMPLANT SYSTEM
3y 4m to grant Granted Apr 07, 2026
Patent 12589015
STENT DELIVERY SYSTEM, ENDOSCOPE SYSTEM, AND STENT INDWELLING METHOD
3y 7m to grant Granted Mar 31, 2026
Patent 12582517
SEALING MEMBER FOR PROSTHETIC HEART VALVE
4y 11m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
42%
Grant Probability
82%
With Interview (+40.0%)
3y 10m (~11m remaining)
Median Time to Grant
Low
PTA Risk
Based on 24 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month